Interim report July 1, 2023 – March 31, 2024

26 April, 2024

Summary of the third quarter (2024-01-01 – 2024-03-31)

  • Net sales amounted to MSEK 0,0 (0,0)
  • Operating profit/loss amounted to MSEK -1,5 (-1,6)
  • Earnings per share* SEK -0.08 (-0.08)

Summary of the nine-month period (2023-07-01 – 2024-03-31)

  • Net sales amounted to MSEK 0,0 (0,0)
  • Operating profit/loss amounted to MSEK -3,9 (-3,7)
  • Earnings per share* SEK -0.18 (-0.19)
  • Cash and cash equivalents at the end of the period amounted to MSEK 21,1 (27,1)

* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year.

CEO’s comment

The company’s Phase 1 study regarding OsteoDex’s treatment of multiple myeloma is ongoing and patient recruitment is progressing. Principal investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital, Huddinge. Biomarkers are analysed at the Central Laboratory, Karolinska University Hospital, NKS, Solna. Patients with relapsed/treatment-resistant disease who have received 1-5 prior lines of therapy are included. The primary objective is to confirm safety and tolerability and as a secondary objective to determine possible response to treatment. Documentation of quality of life will also be done (QoL scores).

The first patient was treated in December at Karolinska University Hospital in Huddinge. The first test results from patient 1 were received on January 23 and show a very strong effect on the marker of osteoclast activity (CTX). The patient has now completed the treatment according to the study protocol and now has stable disease. Stable disease means that the disease does not progress (slowed down). The result is important and indicates that Osteodex can slow down relapsed/treatment-resistant disease.

An amendment to the study protocol that means that the Company can follow the patient’s medical history after completion of treatment has now been approved by the relevant authorities. This provides the Company with information on the duration of OsteoDex’s disease-broking effect.

Anders R Holmberg

DexTech – Interim report July 2023 – March 2024